RxDoctor Payments Data

Megan Johnson, MD

Family Medicine · Chico, CANPI 1336288984

Payments from drug & device makers

$2,376in general payments, 2019–2025

Across 132 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$473
  • Daiichi Sankyo Inc.$460
  • Boston Scientific$183
  • Pfizer$166
  • Indivior Inc.$152
  • Novo Nordisk$133
  • plus $809 from 20 others

What the payments were for

  • Food & beverage$2,376100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,376 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$332
Medicare patients
69
Services billed
101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$89,891
JardianceEmpagliflozin71$65,703
JanuviaSitagliptin Phosphate55$60,746
FarxigaDapagliflozin Propanediol36$32,138
EliquisApixaban18$30,265
Breo ElliptaFluticasone/Vilanterol51$27,056
Combivent RespimatIpratropium/Albuterol Sulfate23$22,470
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$12,479
Fiasp FlextouchInsulin Aspart (Niacinamide)14$6,785
Albuterol Sulfate HfaAlbuterol Sulfate157$5,802
Ventolin HfaAlbuterol Sulfate37$3,318
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,175
Gabapentin158$2,181
Levothyroxine Sodium167$1,518
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$133$89,89175 claims
Boehringer IngelheimJardiance, Combivent Respimat$53$88,17294 claims
MerckJanuvia$23$60,74655 claims
AstraZenecaFarxiga$60$32,13836 claims
PfizerEliquis$166$30,26518 claims
GSKBreo Ellipta$18$27,05651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →